Full Description
This book details the state-of-the-art methodological advances for delineating the toxicology and working mechanisms of nanomaterials, microplastics, fine aerosol particulates (PM2.5) as well as emerging organic pollutants. It also provides latest computational approaches for toxicity prediction and risk assessment of nanoscale materials which possess realistic chances to enter the environment and human organism. Written by leading scientists at the frontiers of environmental science and nanomedicine, this book is intended for both young researchers and experienced professionals working in the fields of environmental protection, human health and occupational safety, nanotechnology, material science and nanomedicine, as well as graduate students majoring in environmental and health sciences.
Contents
Chapter 1. Quantification and imaging of nanomaterials in biological samples.- Chapter 2. Tracing and quantifying microplastics in the environment.- Chapter 3. Advances in analytical methods of emerging contaminants.- Chapter 4. Advances in exposome.- Chapter 5. Omics approaches in toxicological studies.- Chapter 6. Recent developments in the eco- and human toxicology of nanomaterials.- Chapter 7. Characterization of nano-bio interactions in nanotoxicology.- Chapter 8. Knowledge gained from co-exposure studies of nanomaterials and chemicals.- Chapter 9. Ecotoxicology of micro- and nanoplastics.- Chapter 10. Advances in the toxicological studies of atmospheric particulate matter.- Chapter 11. Mechanisms of action of emerging contaminants: PPCP.- Chapter 12. Mechanisms of action of emerging contaminants: disinfection byproduct.- Chapter 13. Mechanisms of action of emerging contaminants: substituting industrial chemicals (BPs, flame retardants, PFCs).- Chapter 14. Status of risk assessment of emerging contaminants.- Chapter 15. Environmental risk assessment models for emerging contaminants.- Chapter 16. Developments in in silico risk assessment of nanomaterials and emerging contaminants.- Chapter 17. Application of adverse outcome pathways in risk assessment.
